Ipsen SA
Research Ipsen SA (IPN) on Bullrun: market cap EUR 13.40B, P/E 26.5, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIPN
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 13.40B
- P/E26.5
- Dividend yield1.0%
- Financial periodFY2025
- RevenueEUR 3.93B
- Revenue growth9.9%
- Net incomeEUR 443.50M
- Free cash flowEUR 809.70M
- Gross margin80.9%
Valuation Snapshot
latest market cap is EUR 13.40B; P/E is 26.5; dividend yield is 1.0%.
Peer valuation comparison
Latest P/E is 26.49x versus a Healthcare sector median of 24.46x (8.3% above).
Latest dividend yield is 0.98% versus a Healthcare sector median of 2.11% (53.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 3.93B | EUR 443.50M | EUR 809.70M | 80.9% | 5.32 | EUR 1.53B | EUR 867.10M | EUR 4.34B |
| FY2024 | EUR 3.57B | EUR 345.90M | EUR 133.00M | 80.3% | 4.15 | EUR 678.10M | EUR 426.80M | EUR 4.18B |
| FY2023 | EUR 3.31B | EUR 644.40M | EUR 677.00M | 82.7% | 7.73 | EUR 528.40M | EUR 373.50M | EUR 3.83B |
| FY2022 | EUR 3.16B | EUR 648.60M | EUR 718.50M | 83.3% | 7.81 | EUR 1.17B | EUR 613.30M | EUR 3.34B |
| FY2021 | EUR 2.75B | EUR 646.70M | EUR 813.20M | 84.0% | 7.76 | EUR 814.70M | n/a | EUR 2.74B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 13.40B | 26.5 | 1.0% | 1.6 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.6 EUR, yield 1.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.4 EUR |
| FY2024 | 1.2 EUR |
| FY2023 | 1.2 EUR |
| FY2022 | 1.2 EUR |
| FY2021 | 1 EUR |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ipsen SA's market cap?
Ipsen SA's market capitalization is EUR 13.40B.
What is Ipsen SA's P/E ratio?
Ipsen SA's price-to-earnings (P/E) ratio is 26.5.
Does Ipsen SA pay a dividend?
Ipsen SA has a dividend yield of 1.0%.
What does Ipsen SA do?
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy.